How to buy Freeline Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Freeline Therapeutics stock

Own Freeline Therapeutics stock in just a few minutes.

Freeline Therapeutics Holdings plc is a biotechnology business based in the US. Freeline Therapeutics shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics employs 236 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Freeline Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FRLN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Freeline Therapeutics share price

Use our graph to track the performance of FRLN stocks over time.

Freeline Therapeutics shares at a glance

Information last updated 2021-04-16.
52-week range$11.85 - $21.69
50-day moving average $13.67
200-day moving average $16.03
Wall St. target price$25.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Freeline Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Freeline Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Freeline Therapeutics financials

Gross profit TTM $0
Return on assets TTM -29.77%
Return on equity TTM -57.55%
Profit margin 0%
Book value N/A
Market capitalisation $445.2 million

TTM: trailing 12 months

Shorting Freeline Therapeutics shares

There are currently 29,491 Freeline Therapeutics shares held short by investors – that's known as Freeline Therapeutics's "short interest". This figure is 8.8% down from 32,354 last month.

There are a few different ways that this level of interest in shorting Freeline Therapeutics shares can be evaluated.

Freeline Therapeutics's "short interest ratio" (SIR)

Freeline Therapeutics's "short interest ratio" (SIR) is the quantity of Freeline Therapeutics shares currently shorted divided by the average quantity of Freeline Therapeutics shares traded daily (recently around 11430.620155039). Freeline Therapeutics's SIR currently stands at 2.58. In other words for every 100,000 Freeline Therapeutics shares traded daily on the market, roughly 2580 shares are currently held short.

However Freeline Therapeutics's short interest can also be evaluated against the total number of Freeline Therapeutics shares, or, against the total number of tradable Freeline Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Freeline Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Freeline Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Freeline Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Freeline Therapeutics.

Find out more about how you can short Freeline Therapeutics stock.

Freeline Therapeutics share dividends

We're not expecting Freeline Therapeutics to pay a dividend over the next 12 months.

Freeline Therapeutics overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site